维昇药业：注射用隆培生长激素获批

Group 1 - The National Medical Products Administration has approved the marketing authorization application for Longpei Growth Hormone, which is intended for the treatment of growth hormone deficiency in children aged 3 and above in China [1][2] - Longpei Growth Hormone is a weekly growth hormone replacement therapy that has completed Phase III trials in China and is the only long-acting growth hormone (LAGH) proven to be more effective and equally safe compared to shorter-acting daily injections in positive parallel-controlled trials [1] - The approval marks the first commercialized innovative product for the company, achieving a significant milestone from research and development to commercialization [1] Group 2 - The approval of Longpei Growth Hormone represents a deep implementation of the company's "global innovation, China acceleration" strategy and signifies a critical transition from R&D-driven to market value realization [2] - As the company's products continue to penetrate the market, it is expected to reshape the competitive landscape of the growth hormone industry and drive the industry from "scale expansion" to "value competition" [2] - The company aims to leverage cutting-edge global technology for local transformation, allowing Chinese patients to benefit from global innovations while establishing a foundation for more high-quality innovative drugs to reach the Chinese market [2]